(See also Overview of Thrombotic Disorders Overview of Thrombotic Disorders In healthy people, homeostatic balance exists between procoagulant (clotting) forces and anticoagulant and fibrinolytic forces. Numerous genetic, acquired, and environmental factors can tip... read more .)
Protein Z, a vitamin K–dependent protein, functions as a cofactor to down-regulate coagulation by forming a complex with the plasma protein, Z-dependent protease inhibitor (ZPI). The complex predominantly inactivates factor Xa on phospholipid surfaces.
The consequence of protein Z or ZPI congenital deficiency, or of acquired autoantibodies to protein Z, in the pathophysiology of thrombosis, fetal loss, and cancer (ovarian or gastric) is not completely clear; however, a defect of either protein Z or ZPI may make thrombosis more likely if an affected patient also has another congenital coagulation abnormality (eg, factor V Leiden Factor V Resistance to Activated Protein C (APC) Mutations of factor V make it resistant to its normal cleavage and inactivation by activated protein C, and they predispose to venous thrombosis. (See also Overview of Thrombotic Disorders.)... read more ) or an acquired autoantibody against a phospholipid-bound protein (an antiphospholipid antibody Antiphospholipid Antibody Syndrome (APS) Antiphospholipid antibody syndrome is an autoimmune disorder in which patients have autoantibodies to phospholipid-bound proteins. Venous or arterial thrombi may occur. The pathophysiology is... read more ).
Quantification of protein Z, ZPI, and protein Z autoantibodies is done in specialized regional laboratories by plasma electrophoresis, immunoblotting, and enzyme-linked immunosorbent assay.
It is not yet known whether anticoagulant therapy or prophylaxis is indicated in protein Z or ZPI deficiency.
Drugs Mentioned In This Article
|Drug Name||Select Trade|